论文部分内容阅读
目的:观察依达拉奉治疗急性脑出血的临床疗效和对血浆基质金属蛋白酶-9(MMP-9)水平的影响。方法:60例急性脑出血患者随机分为治疗组和对照组各30例。对照组给予常规治疗,治疗组在对照组治疗基础上加用依达拉奉,并在治疗后24h内和14d进行神经功能缺损评分及血浆MMP-9水平测定。结果:治疗组神经功能缺损评分、血浆MMP-9水平较对照组降低(P<0.05、P<0.01)。结论:依达拉奉可改善急性脑出血患者神经功能,可能与降低MMP-9水平有关。
Objective: To observe the clinical efficacy of edaravone in the treatment of acute intracerebral hemorrhage and its effect on the level of plasma matrix metalloproteinase-9 (MMP-9). Methods: Sixty patients with acute cerebral hemorrhage were randomly divided into treatment group and control group, 30 cases each. The control group was given routine treatment. The treatment group was treated with edaravone on the basis of the control group, and the neurological deficit score and the plasma MMP-9 level were measured 24h and 14d after treatment. Results: Neurological deficit score and plasma MMP-9 level in the treatment group were lower than those in the control group (P <0.05, P <0.01). Conclusion: Edaravone can improve the neurological function in patients with acute cerebral hemorrhage, which may be related to the decrease of MMP-9.